[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337337-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-337337-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","evaluating-the-efficacy-and-safety-of-nivolumab-and-ipilimumab-combination-therapy-compared-to-nivolumab-monotherapy-in-advanced-cancers-excluding-melanoma-a-systemic-review-and-meta-analysis","Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma) - a systemic review and meta-analysis","","Nivolumab (Nivo) and ipilimumab (Ipi) target complementary pathways in cancer therapy, and their combination has shown benefit in some settings, but evidence across advanced malignancies (excluding melanoma) remains inconsistent. A meta-analysis of randomized controlled trials up to September 30, 2023, compared Nivo-Ipi versus Nivo monotherapy, evaluating overall survival and progression-free survival alongside grades 3–4 adverse events and treatment discontinuations.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluating-the-efficacy-and-safety-of-nivolumab-and-ipilimumab-combination-therapy-compared-to-nivolumab-monotherapy-in-advanced-cancers-excluding-melanoma-a-systemic-review-and-meta-analysis/337337/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluating-the-efficacy-and-safety-of-nivolumab-and-ipilimumab-combination-therapy-compared-to-nivolumab-monotherapy-in-advanced-cancers-excluding-melanoma-a-systemic-review-and-meta-analysis/337337.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the meta-analysis?","Question",{"text":63,"@type":64},"To assess the effectiveness and safety of nivolumab plus ipilimumab compared with nivolumab alone in advanced cancers excluding melanoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which outcomes were evaluated in the study?",{"text":68,"@type":64},"Overall survival (OS), progression-free survival (PFS), grades 3–4 adverse events (AEs), and treatment-related discontinuations; secondary outcomes included specific adverse events.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the combination compare with monotherapy for overall survival and PFS?",{"text":72,"@type":64},"Overall survival showed no significant difference (HR 0.97, p=0.61), while PFS had a slight improvement with combination therapy (HR 0.91, p=0.04).",{"name":74,"@type":61,"acceptedAnswer":75},"What safety differences were observed between treatments?",{"text":76,"@type":64},"Treatment-related grades 3–4 AEs and treatment-related discontinuations were higher with the combination, with increased hepatotoxicity, GI toxicity, pneumonitis, dermatitis, and endocrine dysfunction.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},337337,1790193931,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":116,"preview_page_count":33,"preview_urls":149},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Rangwala etal.  \nJournal of the Egyptian National Cancer Institute (2024) 36:14  \n[https://doi.org/10.1186/s43046-024-00218-2](https://doi.org/10.1186/s43046-024-00218-2)  \nJournal of the Egyptian National Cancer Institute  \n META-ANALYSIS Open Access  \nEvaluating the efficacy and safety    \nof nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis  \nHussain Sohail Rangwala 1* , Hareer Fatima1, Mirha Ali1, Sailesh Sunder2, Sonia Devi3, Burhanuddin Sohail Rangwala 1 and Syed Raza Abbas4  \nAbstract  \nBackground Nivolumab (Nivo) and ipilimumab (Ipi) have revolutionized cancer treatment by targeting different pathways. Their combination shows promising results in various cancers, including melanoma, but not all studies have demonstrated significant benefits. A meta-analysis was performed to assess the effectiveness and safety of NivoIpi compared to Nivo alone in advanced cancer types (excluding melanoma) .  \nMethods Following PRISMA guidelines, we conducted a meta-analysis up to September 30, 2023, searching databases for randomized controlled trials (RCTs) . We focused on advanced solid malignancies (excluding melanoma) with specific Nivo and Ipi dosing. Primary outcomes were overall survival (OS), progression-free survival (PFS), grades 3–4 adverse events (AEs), and treatment-related discontinuations. Secondary outcomes included specific adverse events. Statistical analysis in Review Manager included hazard ratio (HR) and risk ratio (RR), assessing heterogeneity (Higgins I2) .  \nResults Nine RCTs, involving 2152 patients covering various malignancies, were analyzed. The Nivo plus Ipi  \ngroup exhibited a median OS of 12.3 months and a median PFS of 3.73 months, compared to monotherapy  \nwith 11.67 months and 3.98 months, respectively. OS showed no significant difference between Nivo and Ipi combination and Nivo alone (HR = 0 . 97, 95% CI: 0.88 to 1. 08, p = 0 . 61) . PFS had a slight improvement with combination therapy (HR = 0 . 91, 95% CI: 0.82 to 1. 00, p = 0 . 04) . Treatment-related cumulative grades 3–4 adverse events were higher with Nivo and Ipi (RR = 1 . 52, 95% CI: 1.30 to 1. 78, p \u003C 0. 00001), as were treatment-related discontinuations (RR = 1 . 99, 95% CI: 1.46 to 2 . 70, p \u003C 0. 0001) . Hepatotoxicity (RR = 2 .42, 95% CI: 1.39 to 4 . 24, p = 0 . 002), GI toxicity (RR = 2 . 84, 95% CI:  \n1.44 to 5 . 59, p = 0 . 002), pneumonitis (RR = 2 . 29, 95% CI: 1.24 to 2 . 23, p = 0 . 008), dermatitis (RR = 2 . 96, 95% CI: 1.08 to 8 . 14, p = 0 . 04), and endocrine dysfunction (RR = 6 . 22, 95% CI: 2.31 to 16. 71, p = 0 . 0003) were more frequent with Nivo and Ipi. Conclusions Combining nivolumab and ipilimumab did not significantly improve overall survival compared to nivolumab alone in advanced cancers (except melanoma) . However, it did show slightly better PFS at the cost  \n*Correspondence: Hussain Sohail Rangwala[srangwala01@gmail.com](srangwala01@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/","cbCainvVHYCamIEq","https://ap.wps.com/l/cbCainvVHYCamIEq","pdf",2308321,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n## Background","[{\"question\":\"What was the purpose of the meta-analysis?\",\"answer\":\"To assess the effectiveness and safety of nivolumab plus ipilimumab compared with nivolumab alone in advanced cancers excluding melanoma.\"},{\"question\":\"Which outcomes were evaluated in the study?\",\"answer\":\"Overall survival (OS), progression-free survival (PFS), grades 3–4 adverse events (AEs), and treatment-related discontinuations; secondary outcomes included specific adverse events.\"},{\"question\":\"How did the combination compare with monotherapy for overall survival and PFS?\",\"answer\":\"Overall survival showed no significant difference (HR 0.97, p=0.61), while PFS had a slight improvement with combination therapy (HR 0.91, p=0.04).\"},{\"question\":\"What safety differences were observed between treatments?\",\"answer\":\"Treatment-related grades 3–4 AEs and treatment-related discontinuations were higher with the combination, with increased hepatotoxicity, GI toxicity, pneumonitis, dermatitis, and endocrine dysfunction.\"}]","Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma) - a systemic review and meta-analysis | PDF",1790018639,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf4187435a97f912fba6f6b007d5da28.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/668c681ec2caab15f56e50ed0accaf1f.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/069c5a3b8a5611ca50cf3afe8a98e130.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e716bafe0a7438ecdf828fec477180e0.webp",980,1301]